ACADEMIA
Cardiologist Sees Promise in Airwin as First PAH Med to Tackle Disease Progression
Airwin (sotatercept), a newly launched treatment for pulmonary arterial hypertension (PAH), heralds an era of therapies aimed at curbing disease progression at its roots, Yoshihiro Fukumoto, a cardiologist at Kurume University School of Medicine, said at an MSD-sponsored seminar on…
To read the full story
Related Article
- MSD Rolls Out Airwin and Welireg in Japan
August 19, 2025
ACADEMIA
- HPV Expert Backs Routine Shots for Males, Urges Broader Assessment
October 7, 2026
- Bosutinib Set to Enter PIII for ALS in Japan in 2027
October 6, 2026
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





